NextPlat (NXPL) Amortization of Deferred Charges (2010 - 2021)

NextPlat's (NXPL) quarterly Amortization of Deferred Charges came in at -$1.0 in Q3 2021, down 100.0% quarter-over-quarter from $924202.0 in Q2 2021.

Analysis

NextPlat (NXPL) Amortization of Deferred Charges (2010 - 2021) Analysis & Trends

NextPlat (NXPL) has reported Amortization of Deferred Charges for 5 consecutive years, with -$1.0 the latest figure, recorded in Q3 2021.

On a quarterly basis, Amortization of Deferred Charges changed N/A year-over-year to -$1.0 in Q3 2021; TTM through Dec 2021 was $1.4 million, a N/A change from a year earlier, with the FY2021 full-year figure at $1.4 million, up 49.01% from the prior year.
Amortization of Deferred Charges was -$1.0 for Q3 2021 at NextPlat, down from $924202.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $924202.0 in Q2 2021 and troughed at -$1.0 in Q3 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	42.34 Bn	38.68 Bn	2.15 Bn
2	Viatris	19.39 Bn	18.50 Bn	1.46 Bn
3	Dr Reddys Laboratories	9.99 Bn	9.85 Bn	396.53 Mn
4	Amneal Pharmaceuticals	5.57 Bn	5.53 Bn	334.51 Mn
5	Bausch Health Companies	2.45 Bn	1.58 Bn	2.10 Bn
6	Ani Pharmaceuticals	1.70 Bn	1.34 Bn	165.89 Mn
7	Alvotech	1.66 Bn	1.52 Bn	2.56 Mn
8	Amphastar Pharmaceuticals	985.90 Mn	695.77 Mn	93.47 Mn
9	Fennec Pharmaceuticals	434.07 Mn	392.82 Mn	17.15 Mn
10	NextPlat	24.77 Mn	12.93 Mn	4.69 Mn

Historic Data

Download Data